News & Analysis as of

Standing › Janssen v Celltrion

Goodwin

Celltrion Seeks Interlocutory Appeal of Standing Issue in Janssen v. Celltrion

Goodwin on

As we previously reported, the United States District Court for the District of Massachusetts denied Celltrion’s motion to dismiss for lack of standing in the Janssen v. Celltrion case. On November 14, 2017, Celltrion filed a...more

Goodwin

Massachusetts District Court Denies Motion to Dismiss in Janssen v. Celltrion

Goodwin on

The United States District Court for the District of Massachusetts has denied Celltrion’s motion to dismiss the action for lack of standing. As we previously reported, Celltrion argued that certain co-owners of the ’083...more

Goodwin

Celltrion Files Brief and Motion to Compel in Infliximab Litigation

Goodwin on

As we previously reported, Celltrion has moved to dismiss Janssen v. Celltrion for lack of standing. On Monday, Celltrion filed its reply brief in further support of that motion. ...more

Goodwin

Janssen v. Celltrion: Celltrion moves to dismiss for lack of standing

Goodwin on

As we previously reported regarding Janssen v. Celltrion, after the district court postponed trial and heard oral argument on the damages issues related to Celltrion’s challenge to Janssen’s standing, the Court set a deadline...more

Goodwin

Janssen v. Celltrion: Trial Postponed, Briefing and Hearings Scheduled on Standing, Damages Issues

Goodwin on

As we previously reported, a jury trial in the ongoing infliximab biosimilar litigation, Janssen v. Celltrion (D. Mass., J. Wolf), was scheduled to begin on February 13, 2017. The district court, however, recently cancelled...more

5 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide